Relapsed Refractory Chronic Lymphocytic Leukemia clinical trials

Explore recruiting relapsed refractory chronic lymphocytic leukemia clinical trials.

Recruiting relapsed refractory chronic lymphocytic leukemia studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Chronic Lymphocytic Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia

Norway, Sweden, Denmark, Spain, Netherlands, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in patients with relapsed/refractory CLL - (CLL2-BZAG)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Netherlands, Denmark, Belgium, France, Italy, Spain +3 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Multi-Center, Open Label, Uncontrolled, Phase 2a Clinical Trial Evaluating the Safety and Efficacy of the Addition of Ibrutinib to Venetoclax through a MRD-guided Approach in Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia (CLL) IMPROVE (Ibrutinib treatment based on MRD-guided apPROach combined with VEnetoclax)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A dose escalation followed by dose expansion trial to assess safety and tolerability of CAP-100 in subjects with relapsed/refractory chronic lymphocytic leukemia.

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

France, Sweden, Czechia, Austria, Belgium, Germany +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Relapsed Refractory Chronic Lymphocytic Leukemia trials by city

Relapsed Refractory Chronic Lymphocytic Leukemia clinical trials

Recruiting relapsed refractory chronic lymphocytic leukemia studies right now

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies

Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)